Australia - engelsk - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rivastigmine, quantity: 27 mg - drug delivery system, transdermal - excipient ingredients: acrylates copolymer; ethyl acetate; hexane; 2-ethylhexyl acrylate; methyl acrylate; acrylic acid; acrylates/ethylhexyl acrylate copolymer; methylated trimethylated silica - apo-rivastigmine patch is indicated for the treatment of patients with mild, moderate and severe dementia of the alzheimer?s type.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rivastigmine, quantity: 9 mg - drug delivery system, transdermal - excipient ingredients: acrylates copolymer; ethyl acetate; hexane; 2-ethylhexyl acrylate; methyl acrylate; acrylic acid; acrylates/ethylhexyl acrylate copolymer; methylated trimethylated silica - apo-rivastigmine is indicated for the treatment of patients with mild to moderate dementia of the alzheimer's type.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rivastigmine, quantity: 18 mg - drug delivery system, transdermal - excipient ingredients: acrylates copolymer; ethyl acetate; methylated trimethylated silica; hexane; 2-ethylhexyl acrylate; methyl acrylate; acrylic acid; acrylates/ethylhexyl acrylate copolymer - apo-rivastigmine is indicated for the treatment of patients with mild to moderate dementia of the alzheimer's type.

USA - engelsk - NLM (National Library of Medicine)

apotex corp. - rivastigmine tartrate (unii: 9iy2357jpe) (rivastigmine - unii:pki06m3iw0) - rivastigmine 1.5 mg - rivastigmine tartrate capsules are indicated for the treatment of mild to moderate dementia of the alzheimer's type (ad). rivastigmine tartrate capsules are indicated for the treatment of mild to moderate dementia associated with parkinson’s disease (pd). rivastigmine tartrate capsules are contraindicated in patients with: - known hypersensitivity to rivastigmine, other carbamate derivatives or other components of the formulation [see description (11)] - a previous history of application site reaction with rivastigmine transdermal patch suggestive of allergic contact dermatitis, in the absence of negative allergy testing [see warnings and precautions (5.2)] isolated cases of generalized skin reactions have been described in postmarketing experience [see adverse reactions (6.2)] . risk summary there are no adequate data on the developmental risks associated with the use of rivastigmine in pregnant women. in animals, no adverse effects on embryo-fetal development were observed at oral doses 2-4 times the maximu

USA - engelsk - NLM (National Library of Medicine)

sandoz inc - rivastigmine tartrate (unii: 9iy2357jpe) (rivastigmine - unii:pki06m3iw0) - rivastigmine 1.5 mg - rivastigmine tartrate capsules are indicated for the treatment of mild to moderate dementia of the alzheimer's type. rivastigmine tartrate capsules are indicated for the treatment of mild to moderate dementia associated with parkinson’s disease. rivastigmine tartrate is contraindicated in patients with: - known hypersensitivity to rivastigmine, other carbamate derivatives or other components of the formulation [see description (11)] . - a previous history of application site reaction with rivastigmine transdermal patch suggestive of allergic contact dermatitis, in the absence of negative allergy testing [see warnings and precautions (5.2)] . isolated cases of generalized skin reactions have been described in postmarketing experience [see adverse reactions (6.2)] . pregnancy category b there are no adequate and well-controlled studies in pregnant women. reproduction studies conducted in pregnant rats and rabbits at oral doses up to 2.3 mg-base/kg/day, or 2 (rat) and 4 (rabbit) times the maximum recommended hu

USA - engelsk - NLM (National Library of Medicine)

golden state medical supply, inc. - rivastigmine tartrate (unii: 9iy2357jpe) (rivastigmine - unii:pki06m3iw0) - rivastigmine 1.5 mg - rivastigmine tartrate capsules are indicated for the treatment of mild to moderate dementia of the alzheimer's type. rivastigmine tartrate capsules are indicated for the treatment of mild to moderate dementia associated with parkinson’s disease. rivastigmine tartrate capsules are contraindicated in patients with: - known hypersensitivity to rivastigmine, other carbamate derivatives or other components of the formulation [see description (11)]. - a previous history of application site reaction with rivastigmine transdermal patch suggestive of allergic contact dermatitis, in the absence of negative allergy testing [see warnings and precautions (5.2)]. isolated cases of generalized skin reactions have been described in postmarketing experience [see adverse reactions (6.2)] . pregnancy category b   there are no adequate and well-controlled studies in pregnant women. reproduction studies conducted in pregnant rats and rabbits at oral doses up to 2.3 mg-base/kg/day, or 2 (rat) and 4 (rabbit) times the maximum r

USA - engelsk - NLM (National Library of Medicine)

dr. reddy's laboratories limited - rivastigmine tartrate (unii: 9iy2357jpe) (rivastigmine - unii:pki06m3iw0) - rivastigmine 1.5 mg - rivastigmine tartrate capsules are indicated for the treatment of mild-to-moderate dementia of the alzheimer's type (ad). rivastigmine tartrate capsules are indicated for the treatment of mild-to-moderate dementia associated with parkinson’s disease (pd). rivastigmine tartrate is contraindicated in patients with:   - known hypersensitivity to rivastigmine, other carbamate derivatives or other components of the formulation [see description (11) ]  - a previous history of application site reaction with rivastigmine transdermal patch suggestive of allergic contact dermatitis, in the absence of negative allergy testing [see warnings and precautions (5.2) ] isolated cases of generalized skin reactions have been described in postmarketing experience [see adverse reactions (6.2) ]. risk summary there are no adequate data on the developmental risks associated with the use of rivastigmine tartrate in pregnant women. in animals, no adverse effects on embryo-fetal development were observed at oral doses 2 to 4 times the

Frankrike - fransk - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

biogaran - rivastigmine 4 - gélule - 4,5 mg - pour une gélule > rivastigmine 4,5 mg sous forme de : hydrogénotartrate de rivastigmine - psychoanaleptiques - classe pharmacothérapeutique : psychoanaleptiques, anticholinestérasiques - code atc : n06da03.la substance active de rivastigmine biogaran est la rivastigmine.la rivastigmine appartient à une classe de substances appelées inhibiteurs de la cholinestérase. chez les patients atteints de la maladie d’alzheimer ou de démence liée à la maladie de parkinson, la disparition de certaines cellules nerveuses au niveau du cerveau entraîne des taux faibles du neurotransmetteur appelé acétylcholine (une substance qui permet aux cellules nerveuses de communiquer entre elles). la rivastigmine agit en bloquant les enzymes responsables de la destruction de l’acétylcholine : l’acétylcholinestérase et la butylcholinestérase.en bloquant ces enzymes, rivastigmine biogaran permet d’augmenter les taux d’acétylcholine dans le cerveau, contribuant ainsi à diminuer les symptômes de la maladie d’alzheimer et ceux de la démence liée à la maladie de parkinson.rivastigmine biogaran est utilisé pour le traitement des patients adultes atteints de formes légères à modérément sévères de la maladie d’alzheimer, une maladie du cerveau qui affecte progressivement la mémoire, la capacité intellectuelle et le comportement. les gélules et la solution buvable peuvent également être utilisées pour le traitement de la démence chez les patients adultes atteints de la maladie de parkinson.

Frankrike - fransk - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

biogaran - rivastigmine 1 - gélule - 1,5 mg - pour une gélule > rivastigmine 1,5 mg sous forme de : hydrogénotartrate de rivastigmine - psychoanaleptiques - classe pharmacothérapeutique : psychoanaleptiques, anticholinestérasiques - code atc : n06da03.la substance active de rivastigmine biogaran est la rivastigmine.la rivastigmine appartient à une classe de substances appelées inhibiteurs de la cholinestérase. chez les patients atteints de la maladie d’alzheimer ou de démence liée à la maladie de parkinson, la disparition de certaines cellules nerveuses au niveau du cerveau entraîne des taux faibles du neurotransmetteur appelé acétylcholine (une substance qui permet aux cellules nerveuses de communiquer entre elles). la rivastigmine agit en bloquant les enzymes responsables de la destruction de l’acétylcholine : l’acétylcholinestérase et la butylcholinestérase.en bloquant ces enzymes, rivastigmine biogaran permet d’augmenter les taux d’acétylcholine dans le cerveau, contribuant ainsi à diminuer les symptômes de la maladie d’alzheimer et ceux de la démence liée à la maladie de parkinson.rivastigmine biogaran est utilisé pour le traitement des patients adultes atteints de formes légères à modérément sévères de la maladie d’alzheimer, une maladie du cerveau qui affecte progressivement la mémoire, la capacité intellectuelle et le comportement. les gélules et la solution buvable peuvent également être utilisées pour le traitement de la démence chez les patients adultes atteints de la maladie de parkinson.

Canada - fransk - Health Canada

generic medical partners inc - rivastigmine (tartrate hydrogénée de rivastigmine) - capsule - 1.5mg - rivastigmine (tartrate hydrogénée de rivastigmine) 1.5mg - parasympathomemetic (cholinergic) agents